Forte Biosciences, Inc.

Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing FB102, its lead product candidate, for immune-mediated diseases. The company has no approved products and no product revenue, so its value is tied primarily to advancing FB102 through preclinical and clinical development toward regulatory approval.

3.88

3.88

— Forte Biosciences, Inc.
%
Lead product candidate: FB1020% The company’s main therapeutic asset under development for immune-mediated indications such as celiac disease and vitiligo.
Preclinical and clinical development0% Research, trial execution, and data generation needed to advance FB102 through development milestones.
Manufacturing and clinical supply0% Outsourced drug substance and drug product manufacturing, plus supply chain support for studies.
Future partnering and licensing0% Potential collaboration, license, milestone, and royalty economics if the company partners assets.

Forte does not currently sell approved products, so it has no commercial customer base today...

  • Future physicians and patientsprimary

    Would use FB102 if approved for immune-mediated diseases such as celiac disease or vitiligo.

  • Third-party payorssecondary

    Would determine reimbursement and access if the product reaches commercialization.

  • CROs and CMOsprimary

    Provide outsourced trial execution and manufacturing services that enable development.

  • Potential licensing or collaboration partnersemerging

    Could provide funding, development support, or commercialization rights through deals.

Forte is a U.S.-based company and its disclosures emphasize exposure to U.S. capital markets, FDA regulation, and...

  • •Headquartered in the United States
  • •Clinical and regulatory dependence on the FDA and U.S. capital markets
  • •No disclosed product revenue by country
  • •Outsourced CRO/CMO activity may extend beyond the U.S.
  • •Global macro shocks can affect financing, supply, and trial timelines

Forte’s strategy is to concentrate resources on FB102 after discontinuing FB-401, reflecting a narrower and more...

01
Advance FB102 through clinical developmentshort-term

The company’s prospects are highly dependent on FB102 succeeding in early-stage studies and later trials.

02
Secure manufacturing and clinical supplyshort-term

Drug supply and cGMP readiness are required to continue trials and prepare for any future commercialization.

03
Raise additional capital or partner assetsmedium-term

The company will need funding to continue development and may use collaborations to reduce dilution or share risk.

Forte is a pre-revenue biotech with a single lead asset, so clinical failure, financing shortfalls, or regulatory...

critical

Clinical development failure of FB102

The company is almost entirely dependent on one lead candidate, and early data may not predict later-stage success.

Scope
FB102 celiac disease and vitiligo programs
Materiality
high
critical

Financing risk and going-concern pressure

The company has no product revenue and will need additional capital to continue development.

Scope
Operations, trials, and manufacturing
Materiality
high
high

Third-party manufacturing and trial execution risk

Forte relies on CROs and CMOs, so delays or quality issues can disrupt timelines and increase costs.

Scope
Preclinical studies, clinical trials, clinical supply
Materiality
high
high

Intellectual property and patent risk

Without strong patent protection, competitors could develop similar therapies and erode future value.

Scope
FB102 and related technology
Materiality
high
medium

Nasdaq compliance and stock volatility

Prior bid-price noncompliance and volatile trading can reduce market access and investor confidence.

Scope
Public equity financing and liquidity
Materiality
medium
medium

Public health and macroeconomic disruption

Inflation, rate pressure, geopolitical conflict, and epidemics can delay trials and make financing harder.

Scope
Development timelines and capital markets
Materiality
medium
Research and development expense recognition
Can materially change reported operating loss from quarter to quarter
Accruals for CRO and CMO services
Affects R&D expense and accrued liabilities
Capitalized advance payments
Can shift expense recognition across reporting periods
Cash and short-term investment income
Can partially offset operating losses but is not core operating performance

Fortrea Holdings Inc.

FTRE · Services-Medical Laboratories

Solid Biosciences Inc.

SLDB · Biological Products, (No Diagnostic Substances)

Neurogene Inc.

NGNE · Pharmaceutical Preparations

Fortress Biotech, Inc.

FBIO · Pharmaceutical Preparations

Tyra Biosciences, Inc.

TYRA · Pharmaceutical Preparations

Inmune Bio, Inc.

INMB · Biological Products, (No Diagnostic Substances)

: 28/04/2026